Colleen Hanley

Mersana Therapeutics Inc (NASDAQ: MRSN) is closing out its first year as a public company, and in that time it’s cleared an investigational new drug application and earned endorsements from four Street analysts. Baird Equity Research expects the biotech will get even better with time. The...